Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy

Kidney International

Volumn 56, Issue 2, 1999, Pages 714-719

  Campistol, Josep M ^a   Iñigo, Pablo ^a   Jimenez, Wladimiro ^a   Lario, Sergio ^a   Clesca, Paul H ^a   Oppenheimer, Federico ^a   Rivera, Francisca ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Chronic nephropathy; Endothelin; Fibrogenesis; Proteinuria; Renal allograft

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; LOSARTAN; NITRATE; NITRITE; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ANALYSIS; FIBROGENESIS; GENOTYPE; HUMAN; KIDNEY ALLOGRAFT; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEINURIA;

EID: 0032784820     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00597.x     Document Type: Article

References (31)

1. 1. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, BURDICK JF, COHEN AH, COLVIN RB, CROKER BP, DROZ D, DUNNILL MS, HALLORAN PF, HÄYRY P, JENNETTE JC, KEOWN PA, MARCUSSEN N, MIHATSCH MJ, MOROZUMI K, MYERS BD, NAST CC, OLSEN S, RACUSEN LC, RAMOS EL, ROSEN S, SACHS DH, SALOMON DR, SANFILIPPO F, VERANI R, VON WILLEBRAND M, YAMAGUCHI Y: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney lut 44:411-422, 1993
2. 2. MATAS AJ, BURKE JF JR. DEVAULT GA JR, MONACO A, PIRSCH JD: Chronic rejection. J Am Soc Nephrol 4(Suppl: 8):S23-S29, 1994
3. 3. EDDY AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508, 1996
4. 4. BORDER WA, NOBLE NA: Transforming growth factor β in tissue fibrosis, N Engl J Med 331:1286-1292, 1994
5. 5. BORDER WA, NOBLE NA: Transforming growth factor-β. Sci Am Sci Med 2:68-77, 1995
6. 6. KAGAMI S, KUHARA T, OKADA K, KURODA Y, BORDER WA, NOBLE NA: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 51:646-671, 1997
7. 7. SHIHAB FS, TANNER AM, SHAO Y, WETFER MI: Expression of TGF-heta 1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 50:1904-1913, 1996
8. 8. HORVATH LZ, FRIESS H, SCHILLING M, BORISCH B, DEFLORIN J. GOLD LI, KORC M, BUCHLER MW: Altered expression of transforming growth factor-beta in chronic renal rejection. Kidney Int 50:489-498, 1996
9. 9. SUTHANTHIRAN M, KHANNA A, CUKRAN D, ADHIKARLA R, SHARMA VK, SINGH T, AUGUST P: Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int 53:639-644, 1998
10. 10. BORDER WA, NOBLE NA: Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 31:181-188, 1998
11. 11. KHANNA A, KAPUR S, SHARMA V, LI B, SUTHANTHIRAN M: In vivo hyperexpression of transforming growth factor β1 in mice: Stimulation by cyclosporine. Transplantation 63:1037-1039, 1997
12. 12. SHIHAB FS, BENNET WM, TANNER AM, ANDOH TF: Angiotensin tl blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int 52:660-673, 1997
13. 13. PERELLA MA, JAIN MK, LEE ME: Role of TGF-beta in vascular development and vascular reactivity. Miner Electrolyte Metab 24:136-143, 1998
14. 14. GELLAI M: Physiological role of endothelin in cardiovascular and renal hemodynamics: Studies in animals. Curr Opin Nephrol Hypertens 6:64-68, 1997
15. 15. PERRELLA MA, PATTERSON C, TAN L, YET SF, HSIEH CM, YOSHIZUMI M, LEE ME: Suppression of interleukin-1 beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth faclor-betal in vascular smooth muscle cells: Evidence for mechanisms other than NF-kappaB. J Biol Chem 271:13776-13780, 1996
16. 16. MATAS AJ: Chronic rejection-definition and correlates. Clin Transplant 8:162-167, 1994
17. 17. ISONIEMI H, TASKINEN E, HAYRY P: Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 58:1195-1198, 1994
18. 18. MISKO PT, SCHILLING RJ, SALVEMINI D, MOORE WM, CURRIE MG: A fiuorometric assay for the measurement of nitrite in biological samples. Ann Biochem 214:11-16, 1993
19. 19. PCR Protocols: A Guide to Methods and Applications. Edited hy INNIS MA, GELFAND DH, SNINSKY JJ, WHITE TJ, San Diego, Academic Press, 1989, pp 146-148
20. 20. FRENÁNDEZ-LLAMAS P, POCH E, ORIOLA J, BOTEY A, COLL E, DARNELL A, RIVERA F, REVERT LL: Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis. Kidney Int 53:1743-1747, 1998
21. 21. MATTHEWS JN, ALTMAN DG, CAMPBELL MJ, ROYSTON P: Analysis of serial measurements in medical research. BMJ 300:230-235, 1990
22. 22. COTTONE S, VADALA A, VELLA MC, NARDI E, MULE G, CONTORNO A, RICCOBENE R, CERASOLA G: Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic ATI-receptor blockade in human hypertension. Am J Hypertens 11:548-553, 1998
23. 23. CASTILLO D, CAMPISTOL JM, GUIRADO L, CAPDEVILLA I., MARTÍNEZ. JG. PEREIRA P, BRAVO J, PÉREZ, R: Efficacy and safely of losartan in the treatment of hypertension in renal transplant recipients: Results of a multicenter study. Kidney Int 54(Suppl 68): S135-S139, 1998
24. 24. BOCHICCHIO T, SANDOVAL G, RON O, PEREZ-GROVAS H, BORDES J, HERRERA-ACOSTA J: Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 38;873-879, 1990
25. 25. GANSEVOORT RT, DE ZEEUW D, SHAHINFAR S, REDFIELD A, DE JONG PE: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 12(Suppl 2):S37-S42, 1994
26. 26. PETERS H, BORDER WA, NOBLE NA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1570-1580, 1998
27. 27. BORDER WA, NOBLE NA: Evidence that TGF-β should be a therapeutic target in diabetic nephropalhy. (editorial) Kidney Int 54:1390-1391, 1998
28. 28. SANDERSON N, FACTOR VM, NAGY P, KOPP J, KONDAIAH P, WAKEFIELD L, ROBERTS AB, SPORN MB, THORGEIRSSON SS: Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92:2572-2576, 1995
29. 29. COTTON SA, HERRICK AL, JAYSON MI, FREEMONI AJ: TGF-β1, a role in systemic sclerosis? J Pathol 184;4-6, 1998
30. 30. STULA M, PINTO YM, GSCHWEND S, TELSMAN AC, VAN GILST WH, BOHM M, DIETZ, R, PAUL M: Interaction of the renin-angiotensin system and the endothelin system in cardiac hypertrophy. J Cardiovasc Pharmacol 31(Suppl 1):S403-S405, 1998
31. 31. MCKAY S, DE JONGSTE JC, SAXENA PR, SHARMA HS: Angiotensin II induces hypertrophy of human airway smooth muscle cells: Expression of transcription factors and transforming growth factor-β1. Am J Respir Cell Mol Biol 18:823-833, 1998